<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9554">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05695495</url>
  </required_header>
  <id_info>
    <org_study_id>BASEC 2022-01224</org_study_id>
    <nct_id>NCT05695495</nct_id>
  </id_info>
  <brief_title>Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)</brief_title>
  <acronym>DMT BDR</acronym>
  <official_title>Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      N,N-dimethyltryptamine (DMT) is a psychoactive substance with similar effects such as LSD or&#xD;
      psilocybin. However, DMT is less well characterized than the latter substances. The present&#xD;
      study is a modern randomized cross-over trial, investigating different intravenous DMT&#xD;
      boluses over a broad dose range. Thus, different doses will be tested and related to&#xD;
      subjective and autonomic effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      N,N-dimethyltryptamine (DMT) is a naturally-occurring psychedelic substance widely used in&#xD;
      recreational and spiritual settings (Ayahuasca). DMT is considered a tool to induce an&#xD;
      altered state of consciousness of interest in psychological and psychiatric research. DMT is&#xD;
      rapidly metabolized by monoamine oxidase (MAO) A. Therefore, it is inactive when administered&#xD;
      orally and has a very short duration of action when administered parenterally (&lt;20 min).&#xD;
      However, to date no clinical study has investigated dose-response effects over a broad range&#xD;
      of different doses of DMT within the same patient. The aim of the present study is to&#xD;
      experimentally test different intravenous DMT bolus doses over a broad dose range and&#xD;
      investigate the related subjective and autonomic effects in order to establish a precise&#xD;
      dose-response relationship of DMT in healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2023</start_date>
  <completion_date type="Anticipated">January 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>In the randomized arm, subjects will be administered intravenous DMT in 4 different bolus doses (5, 10, 15, 20mg) or placebo in randomized, counter-balanced order. In the dose escalation arm, subjects will be administered a placebo and a maximum of 5 DMT bolus doses (5, 10, 15, 20, 25mg) in an escalating dose order. In both arms, the bolus applications will be separated by one hour.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Altered states of consciousness profile (OAV)</measure>
    <time_frame>Repeatedly 1 hour after each bolus application</time_frame>
    <description>Altered states of consciousness profile (OAV) consisting of 42 items to be rated on a visual analog scale (0-100 mm), with higher values indicating stronger effects with higher scores representing more intense effects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective effect ratings over time</measure>
    <time_frame>Repeatedly 1 hour after each bolus application</time_frame>
    <description>Participants will be asked by the investigator to repeatedly rate their subjective effects verbally on a Likert scale from 0 to 10 for: &quot;any drug effect&quot;, &quot;good drug effect&quot;, &quot;bad drug effect&quot;, and &quot;fear&quot;. Ratings will be performed before and repeatedly after substance administration and will take approximately 30 sec complete.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychedelic experience questionnnaire (PEQ)</measure>
    <time_frame>Repeatedly 1 hour after each bolus application</time_frame>
    <description>Assesses the emergence and intensity of phenomenons occurring in altered states of consciousness on a 6-point Likert scale ranging from 0 (&quot;not at all&quot;) to 5 (&quot;extremely&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Near death experience content scale (NDE-C)</measure>
    <time_frame>Repeatedly 1 hour after each bolus application</time_frame>
    <description>The Near-Death Experience Content (NDE-C) scale is a tool to assess dimensions of near-death experience on a Likert scale ranging from 0 (&quot;not at all&quot;) to 4 (&quot;extremely&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spiritual Realms Questionnaire (SRQ)</measure>
    <time_frame>Once at the end of study day</time_frame>
    <description>Assesses the spiritual phenomenons elicited by psychedelic substances through 11 main questions to be answered on a total of 65 sub-ordered 100mm visual analog scales once on each study day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Repeatedly in short intervals (2-10 minutes) after each bolus application</time_frame>
    <description>Assessed multiple times on each study day via systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Repeatedly in short intervals (2-10 minutes) after each bolus application</time_frame>
    <description>Assessed multiple times on each study day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma level DMT</measure>
    <time_frame>Repeatedly in short intervals (2-10 minutes) after each bolus application</time_frame>
    <description>Assessed multiple times on each study day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine recovery of DMT</measure>
    <time_frame>Once at the end of study day</time_frame>
    <description>Assessed once on each study day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NEO-Five-Factor-Inventory (NEO-FFI)</measure>
    <time_frame>Baseline</time_frame>
    <description>The NEO-FFI is a self-description questionnaire with 60 items for the measurement of the &quot;big five&quot;: neuroticism, extraversion, openness, agreeableness, and consciousness. It uses a 5-point Likert scale ranging from &quot;completely disagree&quot; to &quot;fully agree.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saarbr√ºcker Personality Questionnaire (SPF)</measure>
    <time_frame>Baseline</time_frame>
    <description>The SPF defines empathy as the &quot;reactions of one individual to the observed experiences of another.&quot; It assesses 28- items on a 5-point Likert scale ranging from &quot;Does not describe me well&quot; to &quot;Describes me very well&quot;. The measure has 4 subscales (Perspective Taking, Fantasy, Empathic Concern, Personal Distress) each made up of 7 different items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elliot Humility Scale (EHS)</measure>
    <time_frame>Baseline</time_frame>
    <description>The Elliot Humility Scale (EHS) is a validated 13-item self-rating measure assessing four subscales, i.e. openness, self-forgetfulness, accurate self-assessment, and focus on others on a 5-point Likert scale ranging from &quot;strongly disagree&quot; to &quot;strongly agree&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Randomized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered intravenous DMT in 4 different bolus doses or placebo in randomized, counter-balanced order. The bolus applications will be separated by one hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose ecalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered a placebo and a maximum of 5 DMT bolus doses in an escalating dose order. The bolus applications will be separated by one hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N,N-Dimethyltryptamine (5mg)</intervention_name>
    <description>Intravenous bolus application over 45 seconds</description>
    <arm_group_label>Dose ecalation</arm_group_label>
    <arm_group_label>Randomized</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N,N-Dimethyltryptamine (10mg)</intervention_name>
    <description>Intravenous bolus application over 45 seconds</description>
    <arm_group_label>Dose ecalation</arm_group_label>
    <arm_group_label>Randomized</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N,N-Dimethyltryptamine (15mg)</intervention_name>
    <description>Intravenous bolus application over 45 seconds</description>
    <arm_group_label>Dose ecalation</arm_group_label>
    <arm_group_label>Randomized</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N,N-Dimethyltryptamine (20mg)</intervention_name>
    <description>Intravenous bolus application over 45 seconds</description>
    <arm_group_label>Dose ecalation</arm_group_label>
    <arm_group_label>Randomized</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N,N-Dimethyltryptamine (25mg)</intervention_name>
    <description>Intravenous bolus application over 45 seconds</description>
    <arm_group_label>Dose ecalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (saline)</intervention_name>
    <description>Intravenous bolus application over 45 seconds</description>
    <arm_group_label>Dose ecalation</arm_group_label>
    <arm_group_label>Randomized</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 25 and 65 years old&#xD;
&#xD;
          2. Sufficient understanding of the German language&#xD;
&#xD;
          3. Understanding of procedures and risks associated with the study&#xD;
&#xD;
          4. Willing to adhere to the protocol and signing of the consent form&#xD;
&#xD;
          5. Willing to refrain from the consumption of illicit psychoactive substances during the&#xD;
             study&#xD;
&#xD;
          6. Abstaining from xanthine-based liquids from the evenings prior to the study sessions&#xD;
             and during the sessions&#xD;
&#xD;
          7. Willing not to operate heavy machinery within 6 h of DMT administration&#xD;
&#xD;
          8. Willing to use double-barrier birth control throughout study participation&#xD;
&#xD;
          9. Body mass index between 18-29 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chronic or acute medical condition&#xD;
&#xD;
          2. Current or previous major psychiatric disorder (e.g. psychotic disorders, mania /&#xD;
             hypomania, anxiety disorders).&#xD;
&#xD;
          3. Psychotic disorder or bipolar disorder in first-degree relatives&#xD;
&#xD;
          4. Hypertension (SBP&gt;140/90 mmHg) or hypotension (SBP&lt;85 mmHg)&#xD;
&#xD;
          5. Hallucinogenic substance use (not including cannabis) more than 20 times or any time&#xD;
             within the previous two months&#xD;
&#xD;
          6. Pregnancy or current breastfeeding&#xD;
&#xD;
          7. Participation in another clinical trial (currently or within the last 30 days)&#xD;
&#xD;
          8. Use of medication that may interfere with the effects of the study medication&#xD;
&#xD;
          9. Tobacco smoking (&gt;10 cigarettes/day)&#xD;
&#xD;
         10. Consumption of alcoholic beverages (&gt;20 drinks/week)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Pharmacology &amp; Toxicology, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthias E Liechti, Prof.Dr.med.</last_name>
      <phone>+41 61 268 68 68</phone>
      <phone_ext>+41</phone_ext>
      <email>matthias.liechti@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Severin B Vogt, Dr. med.</last_name>
      <phone>+41 61 268 68 66</phone>
      <phone_ext>+41</phone_ext>
      <email>severinbenjamin.vogt@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Matthias E Liechti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Severin B Vogt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Livio Erne, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenz N M√ºller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>January 23, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2023</study_first_posted>
  <last_update_submitted>January 23, 2023</last_update_submitted>
  <last_update_submitted_qc>January 23, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N,N-Dimethyltryptamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

